Wang et al. reported that the anti-BP180 Fabs B4 and 19, which lack the Fc portion necessary to activate the complement pathway, show therapeutic potential for bullous pemphigoid both in vitro and in vivo. The gene discussed is COL17A1; the disease is bullous pemphigoid.